RESEARCH

Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study

Francesco Trotta *researcher*^{1,2}, Roberto Da Cas *data manager*¹, Stefania Spila Alegiani *researcher*¹, Maria Gramegna *head of preventive medicine area*³, Mauro Venegoni *expert in pharmacovigilance*⁴, Carlo Zocchetti *head of health service governance area*⁵, Giuseppe Traversa *senior researcher*¹

¹Pharmacoepidemiology Unit, National Centre for Epidemiology, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy;

²Pharmacovigilance Unit, Italian Medicines Agency (AIFA), 00187 Rome, Italy; ³Unit for Preventive Medicine, General Directorate for Health, The Lombardy Region, 20124 Milan, Italy; ⁴Regional Centre for Pharmacovigilance, General Directorate for Health, The Lombardy Region, 20124 Milan, Italy; ⁵Unit for Local Health Service Governance, General Directorate for Health, The Lombardy Region, 20124 Milan, Italy

Abstract

Objective To assess the risk of maternal, fetal, and neonatal outcomes associated with the administration of an MF59 adjuvanted A/H1N1 vaccine during pregnancy.

Design Historical cohort study.

Setting Singleton pregnancies of the resident population of the Lombardy region of Italy.

Participants All deliveries between 1 October 2009 and 30 September 2010. Data on exposure to A/H1N1 pandemic vaccine, pregnancy, and birth outcomes were retrieved from regional databases. Vaccinated and non-vaccinated women were compared in a propensity score matched analysis to estimate risks of adverse outcomes.

Main outcome measures Main maternal outcomes included type of delivery, admission to intensive care unit, eclampsia, and gestational diabetes; fetal and neonatal outcomes included perinatal deaths, small for gestational age births, and congenital malformations.

Results Among the 86 171 eligible pregnancies, 6246 women were vaccinated (3615 (57.9%) in the third trimester and 2557 (40.9%) in the second trimester). No difference was observed in terms of spontaneous deliveries (adjusted odds ratio 1.02, 95% confidence interval 0.96 to 1.08) or admissions to intensive care units (0.95, 0.47 to 1.88), whereas a limited increase in the prevalence of gestational diabetes (1.26, 1.04 to 1.53) and eclampsia (1.19, 1.04 to 1.39) was seen in vaccinated women. Rates of fetal and neonatal outcomes were similar in vaccinated and non-vaccinated women. A slight increase in congenital malformations, although not statistically significant, was present in the exposed cohort (1.14, 0.99 to 1.31).

Conclusions Our findings add relevant information about the safety of the MF59 adjuvanted A/H1N1 vaccine in pregnancy. Residual confounding may partly explain the increased risk of some maternal

outcomes. Meta-analysis of published studies should be conducted to further clarify the risk of infrequent outcomes, such as specific congenital malformations.

Introduction

In June 2009 the World Health Organization announced that the diffusion of influenza A/H1N1 had reached pandemic status.¹ A specific question concerned the effect of the infection during pregnancy. Initial reports highlighted the possibility of severe complications in younger age groups in comparison with previous influenza seasons;^{2,3} moreover, pregnant women were considered to be at higher risk of admission to hospital or to an intensive care unit and of maternal death.^{4,5} The influenza infection also had a negative effect on birth outcomes, in terms of an increased risk of prematurity, low birth weight, and perinatal mortality.⁶⁻⁹ Moreover, a potential role in the development of congenital malformations was suggested.⁹⁻¹¹

Although not previously recommended on a large scale, vaccination against influenza during the second and third pregnancy trimester was deemed an appropriate intervention to prevent maternal morbidity and mortality and to reduce the risk of adverse fetal outcomes.³ In Italy, all women in the second or third pregnancy trimester were advised to have the pandemic vaccine, which was available free of charge within the national health service.¹²

Given the paucity of data on the safety of the vaccination during pregnancy, regulatory authorities, such as the European Medicines Agency, the European Centre for Disease Prevention and Control, and the Heads of Medicines Agencies, suggested strengthening the surveillance systems and conducting epidemiological studies on immunised women.¹³ Thus, several

Correspondence to: G Traversa giuseppe.traversa@iss.it

Extra material supplied by the author (see <http://www.bmj.com/content/348/bmj.g3361?tab=related#webextra>)

studies, sponsored by companies and public institutions, were planned worldwide.¹⁴⁻²⁵

A specific question concerned the potential role of the different adjuvants included in each vaccine.^{13 26 27} In Italy, only the A/H1N1 MF59 adjuvanted formulation (Focetria, manufactured by Novartis) was administered to the population. With the objective of estimating the risk of adverse outcomes during pregnancy, in both mothers and newborns, in association with the pandemic vaccination, we carried out a cohort study in the largest Italian region (Lombardy), the resident population of which amounts to around 10 million inhabitants.

Methods

Study population and design

We retrieved all deliveries in women resident in the Lombardy region, occurring in public or private institutions as well as at home, through the regional birth registry (we included stillbirths if the gestational age exceeded 180 days). The study population included all singleton pregnancies (live births and stillbirths) between 1 October 2009 and 30 September 2010, in women aged at least 12 and up to 55 years, whose delivery took place between 23 and 45 weeks of gestation. In case of multiplicity during the study period, we included only the first pregnancy.

Pregnant women who were immunised with the A/H1N1 pandemic vaccine were eligible for the vaccinated (exposed) cohort. All other pregnant women were eligible for the non-vaccinated (unexposed) cohort.

We excluded pregnancies from the cohort if either chromosomal aberrations or congenital viral infections were reported in the birth registry (supplementary table A). We also excluded women if the pandemic vaccination was administered before the start of pregnancy. We estimated the onset of pregnancy by subtracting the gestational age (weeks of amenorrhoea) from the date of delivery (both types of data are reported in the birth registry). We did not include voluntary abortions and miscarriages (pregnancy loss before 180 days of amenorrhoea) in the study, as the information on gestational age is not recorded.

Exposure to pandemic vaccination

The pandemic vaccine was available only through the vaccination centres of the local health units, which were also in charge of recording the information on immunised patients and date of administration. As most vaccines were administered before the end of 2009, we restricted the study period for ascertainment of exposure to between the beginning of the vaccination campaign (1 October 2009) and 31 March 2010.

We considered pregnant women to be exposed to the vaccine from the day of vaccination. We calculated the gestational age at vaccination (index date) after having determined the onset of pregnancy.

Outcomes

We identified pregnancy and neonatal outcomes. Complications of pregnancy included pre-eclampsia/eclampsia (called eclampsia hereafter), gestational diabetes, in-hospital maternal death (deaths during labour or delivery occurring in a healthcare institution), admission to intensive care unit, and type of delivery. Perinatal deaths comprised stillbirths and in-hospital death of live newborns. We defined stillbirth, according to the Italian legal definition, as the delivery of a dead fetus after 180 days of amenorrhoea. Neonatal outcomes included small for gestational age neonates (defined as live newborns with birth

weight below the 10th centile for their gestational age within the cohort of live births only), admission to neonatal intensive care unit, occurrence of neonatal reanimation, and congenital malformations. We identified newborns as having a congenital malformation if a compatible code, according to ICD-9 (international classification of diseases, 9th revision), was present in either the medical birth registry or the hospital discharge form of the neonate. We retained for the analysis only congenital malformations classified according to EUROCAT (European surveillance of congenital anomalies) guidelines.²⁸ We also developed a composite neonatal morbidity outcome with the aim of identifying potential fetal stress during delivery. The composite outcome was based on the presence of any of the following clinical information/diagnoses: very low five minute Apgar score (≤ 3), acute respiratory distress syndrome, asphyxia, intraventricular haemorrhage, and acute necrotising enterocolitis. Supplementary table B gives details about outcome definitions.

Source of data and potential confounders

We used only routinely collected information in the study and abstracted the following regional databases: birth registry, pandemic vaccination, hospital discharges, drug prescriptions, and clinical investigations. All databases were linkable through a unique, anonymised, personal identifier.

We used the birth registry of the Lombardy region, which is filled in for each delivery, to identify the cohort of pregnant women and to abstract information on parents (for example, education and occupational status), pregnancy (for example, gestational age and parity), and deliveries (for example, weight and Apgar score). The registry also includes a section dedicated to stillbirths and congenital malformations.

The hospital discharge database includes all hospital discharge forms for both mothers and newborns. We used the following information: age, dates of admission and discharge, diagnoses and procedures according to the ICD-9, internal transfer (such as admission to intensive care unit), mother/newborn discharge status (that is, dead/alive).

The drug prescription database contains the information on prescriptions issued to outpatients within the regional health service, and we obtained information on date of prescription, drug, and number of packages. The vaccination database contains information on patients who received the pandemic vaccine and the date of vaccination. We used the clinical investigation database to obtain information on women who were exempted from copayments (disease allowances) because of low income or presenting chronic diseases (such as, diabetes, hypertension, or epilepsy).

We took five main categories of potential confounders into account: demographic characteristics of the mothers, socioeconomic status, history of previous pregnancy(ies), history of selected comorbidities and drugs at pregnancy onset, and healthcare use. Supplementary table C gives details on the specific confounders included in the study. No data were available on alcohol use, smoking status, body mass index, over the counter drugs, and multivitamin supplementation.

Statistical analysis

We reported patients' characteristics by vaccine exposure status. We compared the two groups by using a *t* test for continuous variables and a χ^2 test for categorical ones. Given the large number of potential confounders, we used a propensity score model for multivariate analysis. We applied logistic regression to estimate the probability of each pregnant woman receiving

A/H1N1 vaccination versus remaining unvaccinated. We tested all variables previously mentioned as potential confounders and included in the propensity score those with $P \leq 0.05$: age, nationality, education, mother's occupational status, mother's civil status, previous deliveries, previous live births, previous caesarean deliveries, comorbidities and drugs at pregnancy onset (pulmonary disease, cardiovascular disease, diabetes, antidepressants, antibacterials, autoimmune disease, immunodeficiency condition), total number of different drugs used in the six months before pregnancy onset, and number of deliveries occurring in the hospital. As missing data for the variables included in the propensity score affected 1.3% of the study population, we included in the matched analysis only women with a complete dataset.

We matched women exposed and unexposed to vaccination by propensity score (at the fourth decimal digit) and by gestational age (that is, unexposed women must have had a gestational age at least equal to the gestational age at vaccination of the corresponding exposed woman). We matched up to four unexposed women to each exposed one, and we excluded exposed women with no match from the matched analyses.

We took the decision to conduct the study in the overall population of the Lombardy region as part of the surveillance on the safety of the pandemic vaccine. We identified no predefined hypothesis and did no formal estimate of the sample size.

We did both matched and unmatched analyses. In the unmatched analysis, we considered all outcomes occurring from pregnancy onset to delivery. In the matched analysis, we counted only outcomes from the vaccination date to delivery and from the corresponding index date in the non-vaccinated cohort. We used a conditional logistic regression model to estimate crude and adjusted odds ratios, with 95% confidence intervals. We used Stata software (version 11.2) for the statistical analyses.

We also did a pre-planned sensitivity analysis on the matched cohort to investigate the potential protective role of the "healthy vaccinee effect." In this analysis, we excluded all outcomes occurring in the two weeks after the index date. The risk estimates of the sensitivity analysis were expected to move towards the null in case of a confounding role of the "healthy vaccinee effect."

Results

Study cohort

Between 1 October 2009 and 30 September 2010, 88 934 deliveries occurred in the Lombardy region; we excluded 2763 of these, mainly because of multiple births and residency outside the region, leaving a study cohort of 86 171 women (figure 1). About 7% of the cohort (6246 women) received the A/H1N1 vaccine, mostly in the month of November 2009 (supplementary figure). The vaccination was administered either in the third (3615 women; 57.9%) or second trimester of pregnancy (2557 women; 40.9%), and the median gestational age at vaccination was 27 weeks. Only 74 (1.2%) women were vaccinated in the first trimester.

Immunised women were more frequently of Italian nationality, with a higher socioeconomic status, a greater prevalence of concomitant diseases (such as cardiovascular diseases, pulmonary diseases, or diabetes), and more drug prescriptions before the onset of pregnancy (tables 1 and 2). After matching by propensity score and gestational age, we included 6131 exposed and 23 987 unexposed women in the analysis; the two

groups were well balanced with respect to baseline characteristics (tables 1 and 2).

Pregnancy complications

Vaccinated and non-vaccinated women were similar in terms of proportion of spontaneous deliveries (adjusted odds ratio 1.02, 95% confidence interval 0.96 to 1.08) and post-partum admissions to the intensive care unit (0.95, 0.47 to 1.88). Vaccinated women had a slightly higher risk of eclampsia (adjusted odds ratio 1.19, 1.02 to 1.39) and gestational diabetes (1.26, 1.04 to 1.53) (table 3). We observed only minor differences between matched and unmatched analyses. The risk estimates did not change when we excluded the two weeks following the vaccination from the analysis (table 4).

Fetal and neonatal outcomes

The rates of fetal and perinatal outcomes were very similar between vaccinated and non-vaccinated women in both unmatched and matched cohorts (table 3). The adjusted odds ratio of perinatal deaths (stillbirths and in-hospital deaths) was 1.06 (0.65 to 1.71). The likelihood of a newborn being small for gestational age was not affected by vaccination during pregnancy (adjusted odds ratio 0.95, 0.86 to 1.04). We found no differences between vaccinated and non-vaccinated women with regards to the risk estimates of admissions to neonatal intensive care units, need for reanimation procedures, or the composite outcome suggestive of fetal stress at delivery.

A diagnosis of congenital malformation was present in 3246 (4.1%) newborns in the unexposed cohort and 284 (4.5%) in the vaccinated one. The slight increase in the risk estimate was on the margin of statistical significance (adjusted odds ratio 1.14, 0.99 to 1.31). We observed similar rates of congenital malformation regardless of the trimester of vaccination. When classifying congenital malformations according to the organ system subgroups of EUROCAT, we observed a slight, non-significant, increase in congenital malformations in the vaccinated cohort in most subgroups. The sensitivity analysis did not alter the risk estimates: for instance, the odds ratio for heart defects was 1.22 (0.98 to 1.51) in the matched analysis and 1.25 (1.00 to 1.57) in the sensitivity analysis (tables 3 and 4).

Discussion

This was a large population based cohort study that investigated the association between the MF59 adjuvanted pandemic A/H1N1 vaccination in pregnancy and multiple adverse outcomes. We did not find an increased risk of either fetal or birth outcomes following vaccination, whereas a limited increase in the prevalence of gestational diabetes and eclampsia was observed.

Comparison with other studies

Only a few studies have been conducted on the association between pandemic vaccination and maternal or birth outcomes. Three papers focused on the risk of pre-eclampsia/eclampsia after vaccination.^{14 17 20} Our findings are in line with the risk estimates provided by two of these studies: adjusted odds ratio 1.12 (0.81 to 1.55) and adjusted hazard ratio 1.10 (0.97 to 1.26).^{14 17} In the second study, the comparison was made between women vaccinated during pregnancy with the pandemic A/H1N1 vaccine and those who received the seasonal influenza vaccine.¹⁷ The third study, which compared 18 612 women who received the AS03 adjuvanted vaccine and 136 914 non-vaccinated

women in Sweden, did not suggest any increased risk (0.99, 0.92 to 1.07).²⁰

With regard to gestational diabetes, Heikkinen and colleagues found a protective effect of the MF59 adjuvanted vaccine (0.48, 0.29 to 0.80).¹⁴ However, the study was based on a relatively limited cohort of vaccinated women (n=2295) and the authors recognise that “the significantly decreased odds for gestational diabetes is most likely related to the differential follow-up times, as illustrated by the absence of any effect in the proportional hazard model.” A study carried out in Sweden found no effect for gestational diabetes (0.94, 0.81 to 1.09).²⁰

With regard to congenital malformations, which are considered the most severe birth outcomes, the overall risk estimates seen in our study were comparable to those reported by five other published studies.^{14 16 17 20 24} In particular, the estimate was consistent with the one provided by Heikkinen and colleagues, who were testing the same vaccine composition used in our study. The distribution pattern of congenital malformations was comparable to those already published^{14 20}; the slight imbalance in the prevalence of heart defects in the vaccinated cohort, which is on the margin of statistical significance, is coherent with the findings of Heikkinen.¹⁴ However, our study was not intended to highlight differences in risk within subgroups of congenital malformations and, in this respect, the results should be considered as hypothesis generating. To avoid over-interpretation of our findings, a meta-analysis of the studies that investigated heart defects is needed.

Overall, our findings are consistent with those reported by other studies that tested different vaccine formulations (both adjuvanted and not adjuvanted ones) when considering most of the outcomes tested.

Strengths and limitations of study

We considered many potential confounders (including socioeconomic status), which we identified from multiple databases, allowing increased quality and completeness of data. Moreover, the study design was based on information collected from registries, which allowed an independent selection of confounding factors, exposures, and outcomes.

Many outcomes depend on gestational age. We thus matched exposed and non-exposed women by timing of vaccination during pregnancy, aligning the gestational age (in days) of unexposed women with the gestational age (in days) at vaccination, eliminating this relevant confounder.

To take into account the potential confounding factor attributable to the healthy vaccinee effect (that is, the relative good health of patients at the moment of vaccine administration), we did a sensitivity analysis excluding outcomes occurring in the two week period after vaccination. Overall, the sensitivity analysis shifted the risk estimates toward the null, indicating the presence of such residual confounding.

Unlike other studies, we were not able to control our estimates for some confounding factors such as smoking history, alcohol consumption, and body mass index, which could play a role in the aetiology of different outcomes and may be associated with the decision to be vaccinated. For instance, we found a higher prevalence of underlying risk factors among women undergoing vaccination, which is not surprising as the immunisation was primarily recommended in women with comorbidities. The vaccination rate of 7.2% is similar to the coverage reported by other EU countries²⁰; the relatively low proportion of vaccinated women could be due to the fact that this was the first time that pregnant women without comorbidities were prioritised for vaccination. Pregnant women underwent vaccination at a late

stage of pregnancy in the Lombardy region, and only 74 (1.2%) were vaccinated during the first trimester. This very limited cohort makes unfeasible any evaluation of outcomes, and our data can be useful if added to similar ones in a meta-analysis.

Conclusions

Our findings add to the available body of evidence on the safety of the MF59 adjuvanted pandemic A/H1N1 vaccine in pregnancy. Meta-analysis of published studies should be carried out to better define the risk of less frequent outcomes, such as specific congenital malformations. In comparison with the past, future vaccination campaigns targeted at pregnant women will rely on more sound evidence on the safety of vaccine. Clearly, two other factors—maternal and fetal risks associated with the influenza infection during pregnancy, together with the evidence on the effectiveness of the vaccination—should also be taken into account in decision making.

Contributors: GT, MG, MV, and CZ conceived the study. FT, RDC, SSA, and GT designed the study. FT, RDC, SSA, and GT analysed the data. FT and GT wrote the manuscript. FT, GT, RDC, SSA, MG, MV, and CZ contributed to the discussion and reviewed the manuscript. All authors saw, commented on, and approved the final version of the paper. GT is the guarantor.

Funding: Only public employees of the national or regional health authorities were involved in conceiving, planning, and conducting the study; no additional funding was received.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The study was approved by the ethics committee of the Italian National Institute of Health. Only anonymised data were used.

Transparency: GT affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Data sharing: The authors are willing to collaborate in answering further research questions and to participate in systematic reviews or meta-analyses.

- 1 Chan M. World now at the start of 2009 influenza pandemic. 2009. www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
- 2 Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. *N Engl J Med* 2009;361:674-9.
- 3 Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. *Euro Surveill* 2009;14(33):pii=9309.
- 4 Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al, for the Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet* 2009;374:451-8.
- 5 ANZIC Influenza Investigators and Australasian Maternity Outcomes Surveillance System. Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. *BMJ* 2010;340:c1279.
- 6 Griffith GW, Adelstein AM, Lambert PM, Weatherall JA. Influenza and infant mortality. *BMJ* 1972;3:553-6.
- 7 Nishiura H. Excess risk of stillbirth during the 1918-1920 influenza pandemic in Japan. *Eur J Obstet Gynecol Reprod Biol* 2009;147:115.
- 8 Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies. *Lancet Infect Dis* 2008;8:44-52.
- 9 Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. *Clin Perinatol* 2005;32:727-38.
- 10 Acs N, Bánhidly F, Puhó E, Czeizel AE. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. *Birth Defects Res A Clin Mol Teratol* 2005;73:989-96.
- 11 Czeizel AE, Puhó EH, Acs N, Bánhidly F. Use of specified critical periods of different congenital abnormalities instead of the first trimester concept. *Birth Defects Res A Clin Mol Teratol* 2008;82:139-46.

What is already known on this topic

Pregnant women were prioritised as target group for the 2009-10 pandemic influenza vaccination campaign

The effect of MF59 adjuvanted A/H1N1 vaccine on "hard" pregnancy outcomes, such as gestational diabetes, eclampsia, and congenital malformations, has rarely been explored

Only one industry sponsored study, including 2295 vaccinated women, investigated maternal outcomes and congenital malformations in association with MF59 adjuvanted vaccine

What this study adds

No increased risk of either fetal or birth outcomes was seen following vaccination, whereas a limited increase in the prevalence of gestational diabetes and eclampsia was observed

These findings add to the available body of evidence on the safety of the MF59 adjuvanted pandemic vaccine in pregnancy

In comparison with the past, future vaccination campaigns targeted at pregnant women will rely on more sound evidence on the safety of vaccine

- 12 Ministero del Lavoro, della Salute e delle Politiche Sociali. Misure urgenti in materia di protezione dal virus influenzale A(H1N1). 2009. www.trovanorme.salute.gov.it/dettaglioAtto?completo=si&id=30406.
- 13 European Medicines Agency, European Centre for Disease Prevention and Control, Heads of Medicines Agencies. European strategy for influenza A/H1N1 vaccine benefit-risk monitoring. 2009. www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500044933.pdf.
- 14 Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. *Am J Obstet Gynecol* 2012;207:177.e1-8.
- 15 Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *BMJ* 2012;344:e2794.
- 16 Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. *JAMA* 2012;308:165-74.
- 17 Conlin AM, Bukowski AT, Sevik CJ, De Scisciolo C, Crum-Cianflone NF. Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. *Obstet Gynecol* 2013;121:511-8.
- 18 Fell DB, Sprague AE, Liu N, Yaseen AS 3rd, Wen SW, Smith G, et al, for the Better Outcomes Registry & Network (BORN) Ontario. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. *Am J Public Health* 2012;102:e33-40.
- 19 Häberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *N Engl J Med* 2013;368:333-40.
- 20 Källén B, Olausson PO. Vaccination against H1N1 influenza with Pandemrix® during pregnancy and delivery outcome: a Swedish register study. *BJOG* 2012;119:1583-90.
- 21 Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekblom A, Örtqvist Å, et al. Influenza H1N1 vaccination and adverse pregnancy outcome. *Eur J Epidemiol* 2013;28:579-88.
- 22 Richards JL, Hansen C, Bredfeldt C, Bednarczyk RA, Steinhoff MC, Adjaye-Gbewonyo D, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. *Clin Infect Dis* 2013;56:1216-22.
- 23 Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, et al, for the EVA Study Research Group Estudio Embarazo y Vacuna Antigripal. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. *BMJ* 2013;346:f393.
- 24 Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine* 2012;30:4445-52.
- 25 Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. *PLoS One* 2012;7:e51734.
- 26 Jamieson DJ, Rasmussen SA. The safety of adjuvants in influenza vaccines during pregnancy: what do we know and why do we need them? *Am J Obstet Gynecol* 2012;207:145-6.
- 27 Steinhoff MC, MacDonald NE. Influenza pandemics—pregnancy, pathogenesis, and perinatal outcomes. *JAMA* 2012;308:184-5.
- 28 European surveillance of congenital anomalies (EUROCAT). Malformation coding guides. www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/malformationcodingguides.
- 29 Mereckiene J, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. *Euro Surveill* 2012;17(4):pii=20064.

Accepted: 5 May 2014

Cite this as: *BMJ* 2014;348:g3361

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>.

Tables

Table 1 | Demographics and socioeconomic status. Values are numbers (percentages) unless stated otherwise

Characteristics	Unmatched cohort			Matched cohort		
	Unvaccinated (n=79 925)	Vaccinated (n=6246)	P value	Unvaccinated (n=23 987)	Vaccinated (n=6131)	P value
No of deliveries in 2009 in hospital:						
<500	3425 (4.3)	208 (3.3)	<0.001	815 (3.4)	208 (3.4)	0.77
500-999	15 259 (19.1)	965 (15.5)		3872 (16.1)	956 (15.6)	
1000-1499	18 328 (22.9)	1217 (19.5)		4736 (19.7)	1213 (19.8)	
≥1500	42 913 (53.7)	3856 (61.7)		14 564 (60.7)	3754 (61.2)	
Mean (SD) age at delivery, years	31.7 (5.3)	32.6 (5.0)	<0.001	32.5 (5.0)	32.6 (5.0)	0.35
Age group at delivery:						
<20	1059 (1.3)	58 (0.9)	<0.001	205 (0.9)	57 (0.9)	0.84
20-24	7385 (9.2)	354 (5.7)		1440 (6.0)	352 (5.7)	
25-29	17 557 (22.0)	1168 (18.7)		4588 (19.1)	1147 (18.7)	
30-34	28 091 (35.2)	2331 (37.3)		8829 (36.8)	2298 (37.5)	
35-39	21 011 (26.3)	1892 (30.3)		7274 (30.3)	1847 (30.1)	
40-44	4632 (5.8)	422 (6.8)		1588 (6.6)	410 (6.7)	
≥45	190 (0.2)	21 (0.3)		63 (0.3)	20 (0.3)	
Italian nationality	56 605 (70.8)	4951 (79.3)	<0.001	18 996 (79.2)	4853 (79.2)	0.95
Education (mother and/or father):						
University degree	24 576 (30.8)	2398 (38.4)	<0.001	8989 (37.5)	2342 (38.2)	0.49
Secondary school	54 130 (67.7)	3790 (60.7)		14 836 (61.9)	3744 (61.1)	
Primary school/none	939 (1.2)	45 (0.7)		162 (0.7)	45 (0.7)	
Mother's occupational status:						
Employed	54 889 (68.7)	4668 (74.7)	<0.001	18 058 (75.3)	4592 (74.9)	0.93
Unemployed/seeking first occupation	3551 (4.4)	245 (3.9)		922 (3.8)	241 (3.9)	
Housewife	20 520 (25.7)	1269 (20.3)		4816 (20.1)	1250 (20.4)	
Student/other	773 (1.0)	48 (0.8)		191 (0.8)	48 (0.8)	
Mother's civil status at delivery:						
Single	18 216 (22.8)	1259 (20.2)	<0.001	4961 (20.7)	1249 (20.4)	0.94
Married	57 555 (72.0)	4668 (74.7)		18 028 (75.2)	4620 (75.4)	
Separated/divorced/widowed	2475 (3.1)	200 (3.2)		751 (3.1)	198 (3.2)	
Not declared	936 (1.2)	66 (1.1)		247 (1.0)	64 (1.0)	
Father's occupational status:						
Employed	74 167 (92.8)	5847 (93.6)	<0.01	22 509 (93.8)	5748 (93.8)	0.28
Unemployed/seeking first occupation	2142 (2.7)	135 (2.2)		492 (2.1)	133 (2.2)	
Student/other	281 (0.4)	14 (0.2)		79 (0.3)	13 (0.2)	
Low income allowance	1840 (2.3)	154 (2.5)	0.40	505 (2.1)	149 (2.4)	0.12
Consanguinity between mother and father (relationship of fourth, fifth, or sixth degree)	888 (1.1)	46 (0.7)	0.006	270 (1.1)	46 (0.8)	0.01

Table 2| Pregnancy history and risk factors. Values are numbers (percentages) unless stated otherwise

Characteristics	Unmatched cohort			Matched cohort		
	Unvaccinated (n=79 925)	Vaccinated (n=6246)	P value	Unvaccinated (n=23 987)	Vaccinated (n=6131)	P value
Previous conceptions	46 455 (58.1)	3878 (62.1)	<0.001	14 721 (61.4)	3797 (61.9)	0.42
Previous delivery(ies) (parity):						
0	43 933 (55.0)	3159 (50.6)	<0.001	12 267 (51.1)	3115 (50.8)	0.90
1	26 904 (33.7)	2339 (37.5)		8891 (37.1)	2286 (37.3)	
2	6841 (8.6)	578 (9.3)		2218 (9.2)	565 (9.2)	
≥3	2247 (2.8)	170 (2.7)		611 (2.6)	165 (2.7)	
Live births:						
1	27 039 (33.8)	2358 (37.8)	<0.001	8967 (37.4)	2302 (37.6)	0.94
≥2	8985 (11.2)	747 (12.0)		2832 (11.8)	729 (11.9)	
Stillbirths:						
0	79 410 (99.4)	6202 (99.3)	0.57	23 828 (99.3)	6089 (99.3)	0.85
≥1	515 (0.6)	44 (0.7)		159 (0.7)	42 (0.7)	
Spontaneous abortions:						
0	67 057 (83.9)	5118 (81.9)	<0.001	19 829 (82.7)	5020 (81.9)	0.35
1	10 104 (12.6)	870 (13.9)		3224 (13.4)	861 (14.0)	
≥2	2764 (3.5)	258 (4.1)		934 (3.9)	250 (4.1)	
Voluntary abortions:						
0	75 636 (94.6)	5934 (95.0)	0.20	22 774 (94.9)	5822 (95.0)	0.96
≥1	4289 (5.4)	312 (5.0)		1213 (5.1)	309 (5.0)	
Previous caesarean deliveries:						
0	71 548 (89.5)	5472 (87.6)	<0.001	21 103 (88.0)	5387 (87.9)	0.94
1	7127 (8.9)	679 (10.9)		2533 (10.6)	651 (10.6)	
≥2	1250 (1.6)	95 (1.5)		351 (1.5)	93 (1.5)	
Comorbidities and drugs at pregnancy onset:						
Pulmonary diseases	3055 (3.8)	379 (6.1)	<0.001	1197 (5.0)	361 (5.9)	0.01
Cardiovascular disease	1788 (2.2)	218 (3.5)	<0.001	696 (2.9)	197 (3.2)	0.20
Haematological disease	105 (0.1)	12 (0.2)	0.2	36 (0.2)	11 (0.2)	0.60
Diabetes	258 (0.3)	38 (0.6)	<0.001	94 (0.4)	28 (0.5)	0.48
Neurological and psychiatric diseases	560 (0.7)	65 (1.0)	0.1	207 (0.9)	63 (1.0)	0.22
Inflammatory bowel disease/intestinal anti-inflammatory agents	242 (0.3)	25 (0.4)	0.2	84 (0.4)	24 (0.4)	0.63
Immunosuppressive drugs	53 (0.1)	11 (0.2)	0.002	15 (0.1)	10 (0.2)	0.02
Antidepressants	1273 (1.6)	155 (2.5)	<0.001	518 (2.2)	138 (2.3)	0.66
Antiepileptics	317 (0.4)	29 (0.5)	0.4	126 (0.5)	27 (0.4)	0.40
Drugs for gastrointestinal reflux disease	2339 (2.9)	246 (3.9)	<0.001	854 (3.6)	239 (3.9)	0.21
Contraceptive drugs	1847 (2.3)	155 (2.5)	0.4	604 (2.5)	150 (2.5)	0.75
Drugs for human fertilisation	3134 (3.9)	345 (5.5)	<0.001	1180 (4.9)	333 (5.4)	0.10
Non-steroidal anti-inflammatory drugs	2146 (2.7)	219 (3.5)	<0.001	748 (3.1)	211 (3.4)	0.20
Antibacterial for systemic use	16 794 (21.0)	1712 (27.4)	<0.001	6305 (26.3)	1669 (27.2)	0.14
Thyroid disease	1646 (2.1)	172 (2.8)	<0.001	603 (2.5)	161 (2.6)	0.62
Folic acid before pregnancy onset	2540 (3.2)	268 (4.3)	<0.001	933 (3.9)	260 (4.2)	0.21
Folic acid during first trimester	1589 (2.0)	418 (6.7)	<0.001	543 (2.3)	406 (6.6)	<0.001
Iron supplementation	1110 (1.4)	118 (1.9)	0.001	364 (1.5)	116 (1.9)	0.04
Autoimmune disease	740 (0.9)	99 (1.6)	<0.001	298 (1.2)	89 (1.5)	0.19
Immunodeficiency conditions	537 (0.7)	69 (1.1)	<0.001	207 (0.9)	62 (1.0)	0.27
Rare diseases	293 (0.4)	29 (0.5)	0.2	98 (0.4)	29 (0.5)	0.49

Table 2 (continued)

Characteristics	Unmatched cohort			Matched cohort		
	Unvaccinated (n=79 925)	Vaccinated (n=6246)	P value	Unvaccinated (n=23 987)	Vaccinated (n=6131)	P value
Use of medically assisted reproduction:	901 (1.1)	103 (1.6)	<0.001	345 (1.4)	100 (1.6)	0.26
Type of medically assisted reproduction technique:						
Drug treatment to induce ovulation	70 (0.1)	16 (0.3)	<0.001	34 (0.1)	14 (0.2)	0.29
Intrauterine insemination	114 (0.1)	7 (0.1)		45 (0.2)	7 (0.1)	
Gamete intrafallopian transfer	7 (0.01)	0		1 (0.00)	0	
Fertilisation in vitro and embryo transfer	263 (0.3)	28 (0.5)		89 (0.4)	27 (0.4)	
Intracytoplasmic sperm injection	406 (0.5)	46 (0.7)		165 (0.7)	46 (0.8)	
Other techniques	41 (0.1)	6 (0.1)		11 (0.1)	6 (0.1)	
Previous hospital admission:						
0	65 970 (82.5)	5024 (80.4)	<0.001	19 520 (81.4)	4940 (80.6)	0.25
1	11 700 (14.6)	996 (16.0)		3657 (15.2)	974 (15.9)	
2	1645 (2.1)	168 (2.7)		565 (2.4)	162 (2.6)	
≥3	610 (0.8)	58 (0.9)		245 (1.0)	55 (0.9)	
Drugs used in previous six months:						
0	48 921 (61.2)	3217 (51.5)	<0.001	12 816 (53.4)	3179 (51.9)	0.01
1	17 082 (21.4)	1496 (24.0)		5833 (24.3)	1480 (24.1)	
2	7514 (9.4)	734 (11.8)		2760 (11.5)	722 (11.8)	
3	3375 (4.2)	385 (6.2)		1336 (5.6)	374 (6.1)	
≥4	3033 (3.8)	414 (6.6)		1242 (5.2)	376 (6.1)	

Table 3| Pregnancy, fetal, and neonatal outcomes

	Unmatched cohort analysis			Propensity score matched analysis		
	No (%) of cases		Unadjusted odds ratio (95% CI)	No (%) of cases		Adjusted odds ratio (95% CI)
	Unvaccinated (n=79 925)	Vaccinated (n=6246)		Unvaccinated (n=23 987)	Vaccinated (n=6131)	
Pregnancy outcomes						
Pre-eclampsia/eclampsia	2679 (3.4)	248 (4.0)	1.19 (1.04 to 1.36)	715 (3.0)	219 (3.6)	1.19 (1.02 to 1.39)
Gestational diabetes	1738 (2.2)	183 (2.9)	1.36 (1.16 to 1.59)	444 (1.9)	144 (2.3)	1.26 (1.04 to 1.53)
In-hospital maternal death	2 (0.0)	0	—	0	0	—
Admission to ICU	164 (0.2)	10 (0.2)	0.78 (0.41 to 1.48)	42 (0.2)	10 (0.2)	0.95 (0.47 to 1.88)
Type of delivery: spontaneous v others	53 940 (67.5)	4173 (66.8)	0.96 (0.92 to 1.02)	16 003 (66.7)	4107 (67.0)	1.02 (0.96 to 1.08)
Fetal and perinatal outcomes						
Stillbirths	207 (0.3)	16 (0.3)	0.99 (0.57 to 1.68)	58 (0.2)	16 (0.3)	1.06 (0.61 to 1.85)
In-hospital neonatal death	74 (0.1)	5 (0.1)	0.86 (0.35 to 2.14)	19 (0.1)	5 (0.1)	1.04 (0.39 to 2.78)
Perinatal death	281 (0.4)	21 (0.3)	0.96 (0.60 to 1.52)	77 (0.3)	21 (0.3)	1.06 (0.65 to 1.71)
Neonatal outcomes						
Small for gestational age	7947 (9.9)	570 (9.1)	0.91 (0.83 to 0.99)	2307 (9.6)	562 (9.2)	0.95 (0.86 to 1.04)
Admission to neonatal ICU	1639 (2.1)	148 (2.4)	1.16 (0.97 to 1.38)	492 (2.1)	146 (2.4)	1.14 (0.95 to 1.37)
Neonatal reanimation	724 (0.9)	59 (0.9)	1.04 (0.80 to 1.36)	203 (0.8)	58 (0.9)	1.12 (0.83 to 1.50)
Composite outcome	2415 (3.0)	180 (2.9)	0.95 (0.82 to 1.11)	710 (3.0)	176 (2.9)	0.96 (0.81 to 1.13)
Congenital malformations:*	3246 (4.1)	284 (4.5)	1.13 (0.99 to 1.28)	945 (3.9)	276 (4.5)	1.14 (0.99 to 1.31)
Nervous system	148 (0.2)	14 (0.2)	1.21 (0.67 to 2.15)	45 (0.2)	13 (0.2)	1.09 (0.58 to 2.02)
Eye	28 (0.04)	3 (0.05)	1.37 (0.42 to 4.51)	8 (0.03)	3 (0.05)	1.50 (0.40 to 5.65)
Ear, face, and neck	71 (0.1)	10 (0.2)	1.80 (0.88 to 3.61)	27 (0.1)	10 (0.2)	1.42 (0.69 to 2.94)
Congenital heart defects	1269 (1.6)	113 (1.8)	1.14 (0.94 to 1.39)	351 (1.5)	110 (1.8)	1.22 (0.98 to 1.51)
Respiratory	52 (0.1)	7 (0.1)	1.72 (0.72 to 3.94)	13 (0.1)	7 (0.1)	2.00 (0.79 to 5.07)
Orofacial clefts	86 (0.1)	4 (0.1)	0.59 (0.19 to 1.68)	20 (0.1)	3 (0.05)	0.54 (0.16 to 1.84)
Digestive system	262 (0.3)	23 (0.4)	1.12 (0.72 to 1.75)	74 (0.3)	23 (0.4)	1.18 (0.73 to 1.89)
Abdominal wall defects	15 (0.02)	2 (0.03)	1.71 (0.39 to 7.46)	2 (0.01)	2 (0.03)	4.00 (0.56 to 28.40)
Urinary	423 (0.5)	34 (0.5)	1.03 (0.71 to 1.48)	128 (0.5)	32 (0.5)	0.98 (0.67 to 1.45)
Genital	20 (0.03)	0	—	6 (0.03)	0	—
Limb	972 (1.2)	82 (1.3)	1.08 (0.86 to 1.35)	288 (1.2)	80 (1.3)	1.09 (0.85 to 1.40)
Other anomalies	78 (0.1)	8 (0.1)	1.31 (0.63 to 2.72)	24 (0.1)	8 (0.1)	1.33 (0.60 to 2.97)

ICU=intensive care unit.

*At least one.

Table 4| Sensitivity analysis on pregnancy, fetal, and neonatal outcomes: propensity score matched analysis

	No (%) of cases		Adjusted odds ratio (95% CI)
	Unvaccinated (n=22 145)	Vaccinated (n=5776)	
Pregnancy outcomes			
Pre-eclampsia/eclampsia	675 (3.0)	210 (3.6)	1.19 (1.01 to 1.39)
Gestational diabetes	422 (1.9)	139 (2.4)	1.25 (1.03 to 1.52)
In-hospital maternal death	0	0	—
Admission to ICU	39 (0.2)	10 (0.2)	1.04 (0.52 to 2.09)
Type of delivery: spontaneous v others	14 841 (67.0)	3875 (67.1)	1.00 (0.94 to 1.07)
Fetal and perinatal outcomes			
Stillbirths	49 (0.2)	14 (0.2)	1.10 (0.60 to 2.01)
In-hospital neonatal death	16 (0.1)	4 (0.1)	0.98 (0.33 to 2.95)
Perinatal death	65 (0.3)	18 (0.3)	1.07 (0.63 to 1.82)
Neonatal outcomes			
Small for gestational age	2134 (9.6)	523 (9.1)	0.93 (0.84 to 1.03)
Admission to neonatal ICU	416 (1.9)	128 (2.2)	1.16 (0.95 to 1.42)
Neonatal reanimation	174 (0.8)	56 (1.0)	1.24 (0.92 to 1.68)
Composite outcome	646 (2.9)	158 (2.7)	0.92 (0.77 to 1.02)
Congenital malformations:*	873 (3.9)	260 (4.5)	1.14 (0.99 to 1.31)
Nervous system	40 (0.2)	12 (0.2)	1.15 (0.60 to 2.19)
Eye	8 (0.04)	3 (0.1)	1.46 (0.39 to 5.50)
Ear, face, and neck	26 (0.1)	10 (0.2)	1.36 (0.65 to 2.84)
Congenital heart defects	319 (1.4)	105 (1.8)	1.25 (1.00 to 1.57)
Respiratory	13 (0.1)	6 (0.1)	2.00 (0.79 to 5.01)
Orofacial clefts	17 (0.1)	3 (0.1)	0.64 (0.18 to 2.22)
Digestive system	69 (0.3)	22 (0.4)	1.17 (0.72 to 1.89)
Abdominal wall defects	2 (0.00)	2 (0.03)	4.00 (0.61 to 28.39)
Urinary	121 (0.5)	28 (0.5)	0.92 (0.61 to 1.39)
Genital	6 (0.03)	0	—
Limb	266 (1.2)	75 (1.3)	1.06 (0.82 to 1.38)
Other anomalies	23 (0.1)	6 (0.1)	1.03 (0.42 to 2.54)

ICU=intensive care unit.

*At least one.

Figure

Flow chart of women included in study cohort